A quiet signal in the blood may tell a decades-ahead story. In a 25-year study of nearly 6,000 British civil servants, UCL researchers report that higher midlife levels of cardiac troponin I, a marker of subtle heart injury, were linked to faster cognitive decline, smaller brain volumes on MRI, and a higher risk of dementia later in life.
The work, published in the European Heart Journal, followed participants who were free of cardiovascular disease and dementia at the outset, aged 45 to 69. Using a high-sensitivity assay, the team measured troponin at three time points and tracked cognition across six waves of testing. Every doubling of troponin was associated with a 10% increase in dementia hazard, and people starting with the highest troponin group had a 38% higher risk than those below the assay’s quantitation limit. In a brain imaging substudy, higher baseline troponin was tied to smaller grey matter volume and greater hippocampal atrophy roughly 15 years later.
The signal seemed to surface long before symptoms. In a nested case-control analysis, individuals who ultimately developed dementia showed consistently higher troponin levels than matched peers from 7 to 25 years prior to diagnosis. The pattern, the authors argue, suggests subclinical myocardial injury could be part of a causal chain, influencing cerebral perfusion and vascular health during a long preclinical window.
Cardiac troponin I is best known as a diagnostic beacon during suspected heart attacks, when levels spike. But at the lower, asymptomatic range now detectable by high-sensitivity assays, troponin can capture ongoing micro-injury or cardiac dysfunction. Picture an invisible flare from the heart, a few molecules at a time, heralding stress on tissue that may also foretell stress on the brain’s delicate networks.
“Poor heart health in middle age puts people at increased risk of dementia in later life.”
The study’s epidemiologic spine is strong. Participants came from the long-running Whitehall II cohort, with dementia outcomes ascertained through linked UK health records up to March 2023. After accounting for demographic factors and major cardiovascular risks, the associations persisted. Cognitive trajectories diverged with age: at 60 and 70, group scores looked similar, but by 80 and 90, those with higher midlife troponin performed measurably worse, roughly equivalent to being 1.4 to 2 years older in cognitive age.
What the Brain Scans Reveal
Among 641 participants with MRI, higher baseline troponin was associated with smaller grey matter volume and more hippocampal atrophy after about 15 years. The size of the effect tracked with aging: the grey matter reduction in the highest troponin group resembled about 2.7 additional years of age, and hippocampal atrophy roughly 3 years. White matter hyperintensities were not significantly linked, though diffusion metrics hinted at microstructural changes. The imaging aligns with a vascular-neurodegenerative overlap hypothesis, where impaired cardiac function diminishes cerebral blood flow and accelerates tissue loss in regions with high metabolic demand.
Importantly, the troponin signal was not confined to those with overt heart disease. Researchers excluded baseline cardiovascular disease and adjusted for blood pressure, cholesterol, diabetes, obesity, smoking, and activity. Sensitivity analyses that considered APOE genotype and kidney function told the same story. That resilience, while not proving causality, raises the possibility of troponin as a midlife biomarker for brain risk stratification, alongside conventional scores.
“Damage to the brain seen in people with dementia accumulates slowly over the decades before symptoms develop.”
From Risk Score To Action
Could troponin help build a practical dementia risk score in clinic? The authors think so, but they emphasize validation. High-sensitivity assays are widely available, and modestly elevated values in otherwise healthy adults could flag who might benefit most from aggressive risk control. The 2024 Lancet Commission estimated that 17% of dementia cases might be preventable by improving cardiovascular risks, including hypertension, lipids, inactivity, and obesity. Troponin could help target that prevention window when it matters most, in the 40s, 50s, and 60s, before cognitive curves begin to split.
The study has guardrails. It is observational, predominantly White, and based on civil servants, which may limit generalizability. Dementia policy and diagnostic shifts over two decades could influence timing of recorded diagnoses. And while troponin maps risk, it does not specify mechanism. Still, the triangulation across prospective follow-up, backward trajectories, and imaging strengthens confidence that subclinical myocardial injury is not just statistical noise.
For clinicians and policymakers, the takeaway is pragmatic. Heart and brain health travel together, and small, measurable signals in midlife biology can forecast later-life outcomes with unsettling clarity. For readers, the advice is familiar but newly reinforced by a molecular thread: control blood pressure, manage cholesterol, move daily, maintain a healthy weight, and avoid smoking. The same choices that spare arteries may also spare neurons.
If future studies confirm these results, midlife troponin could become part of standard risk profiling for cognitive decline, guiding targeted prevention that keeps minds sharper for longer. In the meantime, the molecule whispers the same message each time it rises a notch: protect the heart, protect the brain.
European Heart Journal: 10.1093/eurheartj/ehaf834
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.